With HHS and CMS leaders nominated, President-elect Trump’s team now may move to US FDA evaluation, commissioner candidates.
With a leader for HHS selected, President-elect Trump's transition team soon should shift its focus to FDA.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.
Biotech execs and lobbyists try to explain the Trump Administration's policy strategy and how to thrive in it.
Robert F. Kennedy Jr. will become HHS secretary while retaining his anti-vaccine positions. His first action likely will be creating a new safety commission, which industry must hope holds off more drastic action.
At a lively AAM Access! conference in Florida, AAM President and CEO John Murphy acknowledged the negative effects of potential tariffs, but also suggested that the second Trump Administration could be an opportunity for the generics and biosimilars sectors to advance market reforms.
